Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, A. Vergnenègre et al.|The Lancet Oncology|2012Cited by 5.5k
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1Benjamin Besse, Enriqueta Felip, Rosario García Campelo et al.|Annals of Oncology|2023Cited by 69